SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.

Jones, PW; Donohue, JF; Nedelman, J; Pascoe, S; Pinault, G; Lassen, C (2011) Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. RESPIRATORY RESEARCH, 12. 161- 161 (10). ISSN 1465-993X https://doi.org/10.1186/1465-9921-12-161
SGUL Authors: Jones, Paul Wyatt

[img]
Preview
PDF Published Version
Download (620kB) | Preview

Abstract

Background Relationships between improvements in lung function and other clinical outcomes in chronic obstructive pulmonary disease (COPD) are not documented extensively. We examined whether changes in trough forced expiratory volume in 1 second (FEV1) are correlated with changes in patient-reported outcomes. Methods Pooled data from three indacaterol studies (n = 3313) were analysed. Means and responder rates for outcomes including change from baseline in Transition Dyspnoea Index (TDI), St. George's Respiratory Questionnaire (SGRQ) scores (at 12, 26 and 52 weeks), and COPD exacerbation frequency (rate/year) were tabulated across categories of ΔFEV1. Also, generalised linear modelling was performed adjusting for covariates such as baseline severity and inhaled corticosteroid use. Results With increasing positive ΔFEV1, TDI and ΔSGRQ improved at all timepoints, exacerbation rate over the study duration declined (P < 0.001). Individual-level correlations were 0.03-0.18, but cohort-level correlations were 0.79-0.95. At 26 weeks, a 100 ml increase in FEV1 was associated with improved TDI (0.46 units), ΔSGRQ (1.3-1.9 points) and exacerbation rate (12% decrease). Overall, adjustments for baseline covariates had little impact on the relationship between ΔFEV1 and outcomes. Conclusions These results suggest that larger improvements in FEV1 are likely to be associated with larger patient-reported benefits across a range of clinical outcomes.

Item Type: Article
Additional Information: PubMed ID: 22206353. Copyright: © 2011 Jones et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/3.0/
Keywords: Adrenergic beta-2 Receptor Agonists, Aged, Bronchodilator Agents, Clinical Trials, Phase III as Topic, Evidence-Based Medicine, Female, Forced Expiratory Volume, Humans, Indans, Linear Models, Lung, Male, Middle Aged, Predictive Value of Tests, Pulmonary Disease, Chronic Obstructive, Quinolones, Randomized Controlled Trials as Topic, Recovery of Function, Severity of Illness Index, Time Factors, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Respiratory System, COPD, spirometry, FEV1, health status, dyspnoea, INHALED BRONCHODILATORS, RANDOMIZED-TRIALS, HEALTH-STATUS, EXACERBATIONS, FLUTICASONE, INDACATEROL, PROPIONATE, SALMETEROL, TIOTROPIUM, COPD, spirometry, FEV1, health status, dyspnoea
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: RESPIRATORY RESEARCH
ISSN: 1465-993X
Related URLs:
Dates:
DateEvent
29 December 2011Published
Web of Science ID: WOS:000301715200001
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
URI: http://openaccess.sgul.ac.uk/id/eprint/102737
Publisher's version: https://doi.org/10.1186/1465-9921-12-161

Actions (login required)

Edit Item Edit Item